Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Annals of Surgical Oncology
|
April 7, 2025
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma
Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors
Oliver Bechter, Carmen Loquai, Stephane Champiat, et al.
Annals of Surgical Oncology
|
May 4, 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
The Lancet. Oncology
|
April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
The New England Journal of Medicine
|
November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutation
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Paolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
JAMA Oncology
|
November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Journal for Immunotherapy of Cancer
|
August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
Plos One
|
April 16, 2015
Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study
Iván Márquez-Rodas, Manuel Martín González, Eduardo Nagore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Annals of Surgical Oncology
|
April 7, 2025
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma
Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors
Oliver Bechter, Carmen Loquai, Stephane Champiat, et al.
Annals of Surgical Oncology
|
May 4, 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
The Lancet. Oncology
|
April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
The New England Journal of Medicine
|
November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutation
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Paolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
JAMA Oncology
|
November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Journal for Immunotherapy of Cancer
|
August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
Plos One
|
April 16, 2015
Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study
Iván Márquez-Rodas, Manuel Martín González, Eduardo Nagore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
Page
of 10